CNAT Key Statistics, Chart & Performance
The current stock price of CNAT is 0.556 null. In the past month the price increased by 61.16%. In the past year, price decreased by -28.02%.
CNAT Latest News, Press Relases and Analysis
About CNAT
Company Profile
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Company Info
Conatus Pharmaceutic
16745 W. Bernardo Dr. Suite 250
San Diego CA 92127
CEO: Steven J. Mento
Phone: 858-376-2600
Conatus Pharmaceutic / CNAT FAQ
Can you describe the business of Conatus Pharmaceutic?
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
What is the current price of CNAT stock?
The current stock price of CNAT is 0.556 null. The price increased by 0.18% in the last trading session.
Does CNAT stock pay dividends?
CNAT does not pay a dividend.
What is the ChartMill rating of Conatus Pharmaceutic stock?
CNAT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of Conatus Pharmaceutic (CNAT)?
Conatus Pharmaceutic (CNAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
Would investing in Conatus Pharmaceutic be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CNAT.
CNAT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CNAT. When comparing the yearly performance of all stocks, CNAT is one of the better performing stocks in the market, outperforming 72.81% of all stocks.
CNAT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNAT. CNAT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNAT Financial Highlights
Over the last trailing twelve months CNAT reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 42.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -68.87% | ||
| ROA | -53.86% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |